Company ProfilePremium

RH Bophelo Limited

Company Profile Analysis

Ticker: RHB.JO

ESOMAR 23 Corporate BadgeISO Certifications Badge
RH Bophelo Limited - Company showcase

Year Founded & Workforce

2016

742 Employees

RH Bophelo Limited logo

RH Bophelo Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

RH Bophelo Limited Overview

ItemDetailSource
Legal nameRH Bophelo LimitedFY2026 AFS
Former nameNewshelf 1388 Proprietary LimitedSENS, 5 Jul 2017
Registration number2016/533398/06FY2026 AFS
Incorporated13 December 2016, Republic of South AfricaFY2026 AFS, note 1
FounderQuinton Zunga (founder, CEO)TradingView profile; Business Day, Jul 2017
Headquarters / registered officeUnit 12, 1st Floor, 1 Melrose Boulevard, Melrose Arch, Johannesburg, 2076FY2026 AFS; SENS 25 Nov 2025
Primary listingJSE Main Board, 12 July 2017; first listed as a SPAC and now an investment entity under Section 15 of the JSE Listings RequirementsSENS; Profile's Handbook 2025
JSE sector classificationFinancials – Closed End InvestmentsProfile's Handbook 2025
Secondary listingRwanda Stock Exchange, by introduction, 1 June 2020FY2021 abridged results
TickersJSE: RHB (vendor alias RHBE; RHB.JO); RSE: RHBSENS
ISINZAE000244737SENS
CUSIPNot applicable / not publicly disclosed (FIGI BBG00H416BS4 per TradingView)TradingView
Fiscal year endLast day of FebruaryAFS
Shares in issue64,691,298 "A" ordinary shares, plus 1 unlisted "B" restrictive share held by the investment managerFY2026 AFS, note 13
Employees (holding company)Not publicly disclosed. The holdco's employee costs were R9.31m in FY2026.FY2026 AFS
Employees (Profile's Handbook)742. The scope is not stated and is likely group/portfolio-wide.Profile's Handbook 2025 Issue 4
Employee 3-year trend——
Investment managerRH Bophelo Management Company (Pty) Ltd (RHBM), external, which holds the "B" shareFY2026 AFS
External auditorForvis Mazars (formerly Mazars); engagement partner Stephan Adlam CA(SA)FY2026 AFS
JSE sponsorBSM Sponsors (Pty) Ltd. Previously Deloitte & Touche Sponsor Services; the change was made between Nov 2025 and May 2026.FY2026 AFS; SENS 30 Jun 2026
RSE sponsorFaida Securities Rwanda LimitedFY2026 AFS
Company secretaryStatucor (Pty) Ltd. In 2021 it was Corporate Vision Consulting.FY2026 AFS; FY2021 results
Transfer secretaryComputershare Investor Services (Pty) LtdSENS
B-BBEE statusLevel 1SENS, 27 Jul 2026
Net asset value (NAV), FY2026R1,096,831,961; NAV per share 1,695.5 centsFY2026 AFS
Market capitalisation (current)About R106.7m at 165c/share × 64.69m shares (analyst-derived). TradingView displays R112.56m (see note).TradingView, Oct 2026
Price / NAVAbout 0.10x, a discount of roughly 90% to reported NAV (analyst-derived)—
Websitewww.rhbophelo.co.zaSENS

RH Bophelo is a small, black-owned, Johannesburg-based investment holding company. It allocates permanent capital to South African healthcare and healthcare-adjacent financial services. It listed on the JSE in 2017 as a R500m special purpose acquisition company and later converted into a Section 15 investment entity. It now holds about R1.15bn of unlisted portfolio investments, all measured at fair value. Roughly 78% of that value sits in an "asset-heavy" cluster of independent, mostly peri-urban private hospitals and related property companies: Africa Healthcare, Rondebosch Medical Centre, Medicare, Vryburg, RH Bell and Fauchard. The remaining ~21% sits in an "asset-light" cluster of pharmaceutical distribution (MMed/1-Pharma), radiology (RazoHealth), dialysis (Renal Healthcare Africa), pathology (Ambit/Pelo) and benefits administration (Wesmart). Its stated purpose is affordable care for lower- and middle-income South Africans. The investment case hinges on the gap between a reported NAV of R16.96 per share and a thinly traded share price of about R1.65. That gap is shaped by external management, a concentrated register dominated by the Public Investment Corporation, and Level-3 valuations.


Company's own description (FY2026 AFS, paraphrased)

The company describes itself as an investment entity listed on the JSE and RSE. It seeks returns for shareholders through equity, quasi-equity and equity-related investments in healthcare and financial services. It names the target areas as operational infrastructure, health insurance, private hospital infrastructure, pharmaceuticals, retail and distribution, and healthcare technology.

It executes this mandate through two wholly owned investment-entity subsidiaries:

  • RH Bophelo Operating Company (Pty) Ltd (RHBO), which holds healthcare investments.

  • RH Financial Services (Pty) Ltd (RHFS), which holds healthcare-related financial services investments.

Portfolio management is outsourced under a shareholder-approved management agreement to RH Bophelo Management Company (Pty) Ltd (RHBM). RHBM is not controlled by the company (FY2026 AFS, notes 1 and 4.1).

In FY2026 the company described its strategy as a deliberate move from an "asset-heavy owner and operator" of healthcare facilities to an "asset-light owner and manager of healthcare assets". The aim is to participate in the broader healthcare value chain through partnerships, scalable operating models and new ventures in pharmacy distribution, pathology, radiology and dialysis (FY2026 AFS, Directors' Report, note 9).

Independent characterisation

Economically, RH Bophelo is a listed, externally managed, permanent-capital private equity vehicle. It invests in a concentrated set of unlisted South African healthcare businesses. Several features follow from its accounting status:

  1. Revenue model. Under IFRS 10 the company and its two sub-holding companies qualify as investment entities. The company therefore does not consolidate its hospitals or distribution businesses. Its "revenue" is made up of:

    • dividends received from RHBO;

    • interest on shareholder loans (mainly the Notamed/RH Bell property loan) and on cash;

    • fair-value gains or losses on the portfolio, which are unrealised and Level-3. No look-through product, service or subscription revenue mix is published in the AFS. The FY2025 Integrated Annual Report summary on AfricanFinancials (an AI-generated summary, unaudited) states that asset-light businesses contributed 32% of "Group revenues" and were growing at more than 15% a year. The underlying Rand revenue is not disclosed in the sources retrieved.

  2. Value-chain position. Through its investees the company sits across several parts of the care chain:

    • acute and day-hospital care: St Helena (Welkom), Fochville, Carletonville, Vryburg, Rondebosch, Medicare, RH Bell, Fauchard, and Platinum via Dorama;

    • hospital property ownership: Magnacorp, Notamed, St Helena property;

    • pharmaceutical wholesale/distribution: MMed, now trading as 1-Pharma;

    • diagnostics: RazoHealth radiology and Ambit/Pelo pathology;

    • renal dialysis: Renal Healthcare Africa;

    • nursing education: AHC Nursing College;

    • emergency medical services: Gerijo EMS;

    • medical-scheme/benefits administration: Wesmart. In December 2021 the IFC described the company as owning eight hospitals and managing fourteen more for third parties through a hospital consulting, commissioning and management subsidiary. Whether that management business is still active is not disclosed in the FY2026 AFS.

  3. Customer types and end-markets. The ultimate payers are medical schemes, insured individuals, self-paying lower- and middle-income patients and, to a degree, the state. At listing in 2017, management said it would serve people who cannot afford private care as currently structured, focusing on small independent hospitals in peri-urban areas (Business Day, July 2017). MMed sells to external pharmacies and to RH-owned pharmacies (FY2024 AFS, note 6.1).

  4. Mix of income (analyst-derived from AFS):

Source: FY2024, FY2025 and FY2026 AFS, statements of profit or loss.

Analytical note on the FY2026 dividend. Dividend income rose to R83.69m in FY2026, but only R15.84m was received in cash (FY2026 cash flow statement). Dividends receivable increased by R11.73m, from R4.80m to R16.53m. The remaining ~R56.1m matches the R56.13m of "capital paid – non cash" on the Norsad loan almost exactly (FY2026 AFS, note 15). Our inference, which the company does not state explicitly, is that most of the FY2026 dividend was settled non-cash: the Norsad holding-company debt was discharged and refinanced at investee level (Africa Healthcare). The headline jump in dividend income is therefore largely a transfer of leverage from the holding company down to the portfolio, not an increase in cash yield.

Strategy

Stated corporate strategy (themes from the FY2025 and FY2026 AFS and IAR summaries, paraphrased)

  1. Asset-light transition. Move from owning and operating healthcare facilities to owning and managing healthcare assets, optimising capital allocation while keeping strategic influence (FY2026 AFS).

  2. Value-chain participation. Grow through partnerships, scalable operating models and new ventures in pharmacy distribution, pathology, radiology and dialysis (FY2024–FY2026 AFS).

  3. Service integration and margin. Management says the asset-light strategy lowers input costs, improves operating margins and enables integration across the portfolio (FY2025 and FY2026 Directors' Reports).

  4. Affordable access. The founding mission is quality care for lower- to middle-income earners in the gap between public and premium private care (2017 listing; company profile).

  5. Digital and AI-enabled care. The FY2025 IAR summary references deployment of AI-powered electronic medical records.

  6. NHI positioning. Management supports the NHI and sees potential participation in future state-led contracting frameworks, while acknowledging risks to funding flows and pricing (FY2026 AFS).

Initiatives in the last 24 months (Oct 2024 – Oct 2026)

InitiativeDateDetailSource
Renal Healthcare Africa JV (dialysis)May 2024 onward51% with Renocare SA; R8.3m equity; fair value R21.9m at FY2026FY2025–FY2026 AFS
RazoHealth radiology rolloutFY2025–FY20263 practices at FY2025, 4 at FY2026; R6.6m and R2.0m deployed. The IAR summary mentions a 15-centre rollout.AFS; FY2025 IAR summary
1-Pharma / MMed consolidation of pharmacy operationsFY20251-Pharma took full operational control of group pharmacy operations; R8m and R5.5m working-capital loansFY2025 IAR summary; AFS
Fauchard supportOct 2024; Sep 2025R1.6m and R0.11m working-capital advancesAFS
Capital-structure resetFY2026Norsad R100m facility discharged and refinanced at asset level (Africa Healthcare). Capitec working-capital facility (prime-linked, annual review, R25m RHBO guarantee, R20m cash pledge). FNB R10m overdraft closed.FY2026 AFS, notes 12 and 15
Office lease renewalOct 2025Three-year extension (right-of-use asset R3.18m)FY2026 AFS
Board renewalJan 2025; Oct 2025Mpelwane, Mashau and Ndhlazi appointed; new ARC chairSENS; AFS
Sponsor changeBetween Nov 2025 and May 2026JSE sponsor moved from Deloitte to BSM SponsorsAFS; SENS
Energy resilienceFY2024 onwardAlternative-energy plan for operating facilities in response to load-sheddingFY2024 AFS

Cost programmes with targets: None publicly disclosed. The H1 FY2026 results referred generically to "cost containment measures".

Medium-term financial targets / guidance

Capital structure: A target "gearing" ceiling of 30% (FY2026 AFS, note 13).

"B" share hurdle: 10% NAV growth baseline, which is a de-facto performance benchmark for the manager.

Explicit guidance: No NAV, earnings or dividend guidance is published.

Historic ambitions, not current guidance: - At listing the company said it would not pay dividends for at least three years.

  • In 2018 the CEO cited a medium-term R5bn portfolio target.

  • In 2021 the IFC announced a planned US$56m raise. None of these appears in recent filings, and the US$56m raise has not been reported as completed.

Products & Services

RH Bophelo does not sell products itself. Its "portfolio" is its investee companies. Each one is profiled below. Fair values, costs and post-tax WACC come from the FY2026 AFS (note 6) unless stated. Investee revenue, beds, theatres and pricing are not publicly disclosed in the AFS.

Asset-heavy segment

(1) Africa Healthcare (Pty) Ltd ("AHC") — 100%

Description: Owns and operates hospitals. The FY2021 results also mentioned pharmaceutical distribution within AHC.

Facilities: Subsidiaries listed in FY2026 are St Helena Private Hospital and St Helena Hospital (Welkom, Free State), AHC Fochville Hospital (Gauteng), The Fountain Private Hospital, RH Pelo Carletonville Hospital (Gauteng) and CFM. St Helena Hospital, Welkom, appears in third-party medical-scheme network lists (LA Health; Bankmed). The Fountain Private Hospital also appears in the LA Health 2026 network list.

Property: In FY2026 the valuation includes only the St Helena property, at R46m and a 14% capitalisation rate. In FY2025 it included St Helena (R53m at 11%) and Fochville (R11m at 12.5%). Dropping Fochville from the property list in FY2026 is not explained in the sections retrieved.

Valuation: Fair value R383.62m (33% of the portfolio). Cost R122.5m. WACC 19.20%. Share of investee net assets (unaudited) R57.19m.

Income to the company FY2026: R15.68m.

Strategic note: AHC is the largest single asset and, per the FY2026 AFS, the level at which debt was refinanced to align debt with the underlying assets.

Original acquisition: 60% announced November 2017; now 100%.

(2) Rondebosch Medical Centre (Pty) Ltd ("RMC") — 100%

Description: Hospital services in Rondebosch, Cape Town. Includes RMC Pharmacy (100%).

Acquisition: 30% initially (2018, per secondary source), plus 70% in March 2020 for R93.75m. Total cost R143.7m.

Valuation: Fair value R199.47m (17%). WACC 19.53%. Share of net assets negative R386.1m. The company attributes the negative net asset value to the IFRS 16 lease effect (FY2024 AFS, note 6.1), which implies a large lease obligation, probably on the hospital premises.

Valuation history: R224.3m in FY2023, R233.2m in FY2024, R195.1m in FY2025 (-R37.1m) and R199.5m in FY2026 (+R5.0m).

Income FY2026: R0.92m.

Other: In March 2023 the company advanced a R6m working-capital loan, of which R1m was repaid in FY2024. Net receipts from RMC were R1.0m in FY2025 and R0.7m in FY2026.

(3) Medicare Private Hospital — 54% of the operating company (BMC Gilliwie), 50.1% of the property company (Magnacorp 84), held through Megafrack

Description: Hospital services plus investment property. The location is not disclosed in the sources reviewed.

Valuation: Fair value R200.43m (17%). Cost R123.5m. WACC 20.44%. Share of net assets R108.63m. The property value in the valuation is R113.2m at an 11% capitalisation rate.

FY2026 fair value change: -R14.25m.

Restatement: The FY2026 AFS restated the FY2025 property value used in sensitivity disclosures from R211m to R122m to reflect the correct attributable share.

Income: Nil in FY2025 and FY2026, against R12.92m in FY2024.

Covenant: Under the Norsad covenants, Medicare EBITDA had to be at least R20m. It was R48.1m in FY2025 (FY2025 AFS, note 27).

(4) Vryburg Private Hospital (Fezinet t/a Vryburg Private Hospital) — 81% via Vryburg Holding Company

Description: Hospital services in Vryburg, North West. It appears in medical-scheme network lists.

Acquisition: 76% of the HoldCo announced in November 2017; now reported at 81%.

Valuation: Fair value R69.59m (6%). Cost R43.85m. WACC 20.53%. Property R25.92m at 11%.

Income FY2026: R2.46m.

History: Received COVID relief shareholder loans of R7.4m in FY2021. Revalued up by R26.7m in FY2025.

(5) RH Bell Clinic (Pty) Ltd and Notamed (Pty) Ltd (property company) — 100%

Description: Hospital/clinic services. The property sits in Notamed. Location not disclosed.

Valuation: Fair value R37.82m. Property R33m at 10%.

Shareholder loan to Notamed: R55.33m at FY2026, measured at fair value and repayable by March 2028 with no fixed instalments. The rate is 7.75% per the FY2026 AFS; the FY2025 AFS stated 10%, a discrepancy noted here. Interest accrued was R4.33m in FY2026.

Security: First-ranking bond under the former Norsad facility.

(6) Fauchard Day Clinic (Fauchard Tandheelkundige Sentrum) — 100%

Description: Day hospital/clinic. "Tandheelkundige" is Afrikaans for "dental", which suggests a dental/day-surgery origin. Listed in medical-scheme networks at Florida (Roodepoort), Gauteng.

Valuation: Fair value R8.0m (R13.0m in FY2025; R14.0m in FY2024), equal to the property value at an 11.5% capitalisation rate. The operating business is therefore valued at nil.

Recent advances: R0.11m in September 2025; R1.6m in October 2024.

(7) Dorama Investments (Pty) Ltd — 100%

Holdings: AHC Nursing College (nursing education), Platinum Private Hospital and Gerijo EMS (emergency medical services), all 100%.

Valuation: Fair value R2.8m. It was written down to R1 in FY2023/FY2024 and rose to R2.8m in FY2025.

Locations: Not disclosed.

Asset-light segment

(8) MMed Distribution Services (Pty) Ltd / 1-Pharma — 100%

Description: Pharmaceutical distributor with distribution licences across South Africa. Sells to external and RH pharmacies. The FY2025 IAR summary states that 1-Pharma took full operational control of the group's pharmacy operations.

Acquisition: 31 May 2023 for R1.

Funding: R4.8m bridging loan in FY2024; R8m in March 2024 (repaid within FY2025); R5.5m in March 2025.

Valuation: Fair value R167.45m (15%). Revalued from R0 to R158.1m in FY2024, to R185.0m in FY2025, then down to R167.5m in FY2026 (-R23.1m). WACC 20.45%.

Income FY2026: R1.47m.

(9) RazoHealth Radiology (Pty) Ltd — 60% JV with a radiologist

Description: Founded 31 July 2023. Originally a management company for radiology practices. The FY2026 AFS says it "operates" the practices: three were operational at the end of FY2025 and four at the end of FY2026. The FY2025 IAR summary refers to the start of a rollout of 15 diagnostic centres (secondary; unaudited summary).

Capital deployed: R0.13m in FY2024, R3.5m in March 2024, R6.6m in FY2025, R2.0m in FY2026.

Valuation: Fair value R40.82m.

(10) Renal Healthcare Africa (Pty) Ltd — 51% JV with Renocare South Africa (Pty) Ltd

Description: Dialysis services. Founded May 2024 with R8.3m of equity from RHBO.

Valuation: Fair value R21.93m (R19.84m in FY2025).

Related entity: "RHB Renal Care (Pty) Ltd" (74%) is also listed as a related party in FY2025. Its role relative to the JV is not explained.

(11) Ambit Health (Pty) Ltd ("Pelo") — 29% associate

Description: Pathology services. Acquired 1 March 2023 for R1.075m.

Valuation: Fair value R5.90m, down from R13.88m in FY2025 (-R7.98m in FY2026).

(12) Wesmart Financial and Administration Solution (Pty) Ltd — 60% via RHFS

Description: Financial and administration solutions (medical-scheme/benefit administration). In FY2020 it operated a cell-captive arrangement with Genric Insurance, backed by a R3m RH Bophelo guarantee.

Valuation: Fair value R3.0m. Shareholder loans of R0.4m in FY2026, R0.5m in FY2025 and R1.1m in FY2024 have each been written off through fair value.

(13) Locumbase (Pty) Ltd — 10%

Description: Not described in the AFS; the name suggests healthcare locum staffing. Written down from R4.0m in FY2022 to nil in FY2024.

Exited / historical holdings

HoldingBusinessExitSource
Genric Insurance Company Ltd (25%, later 30%)Short-term insuranceExited FY2023 for R61.5mFY2021 results; FY2024 AFS
Phelang Bonolo Healthcare Procurement & Management (PBHPM)Healthcare procurement and managementSold for R14m. Classified held for sale in FY2023, completed in FY2024. R8.2m was received by FY2025 and an ECL of R1.17m was raised. In FY2026 the ECL was reversed and the receivable is nil, implying recovery (inference).FY2024–FY2026 AFS
RH 12J LimitedSection 12J venture capital companyDisposed for R2.1m in 2021FY2021 results

Pricing models and flagship offerings

Investee pricing (hospital tariffs, distribution margins, radiology/dialysis tariffs) is not publicly disclosed. Hospital revenue in South Africa is mainly funded through medical-scheme tariffs negotiated with funders. RH Bophelo's facilities appear in restricted-network lists, for example LA Health's Focus network (St Helena, Vryburg, Fauchard, The Fountain), which suggests network-based contracting with schemes.

Financial Narrative

Basis.

  • Company-only IFRS financial statements of an investment entity. There is no consolidation, so "revenue", "gross profit" and "EBITDA" are not native concepts.

  • "Total income" is used as the revenue proxy: investment income (interest, dividends and fair-value movements) plus other income.

  • "Operating income (EBIT)" is analyst-derived as profit before tax plus finance costs.

  • "EBITDA" is EBIT plus depreciation.

  • Gross profit is not applicable.

  • Only FY2022 balance-sheet items carried as opening balances in the FY2024 AFS comparatives are reported. Equity reconciliation implies FY2022 profit after tax of roughly R49.6m–R53.5m; the range depends on whether the R3.9m "B" dividend was charged to equity.

Income statement: notes and sources

Sources: FY2024 AFS (FY2023 comparatives restated to split employee costs and depreciation), FY2025 AFS, FY2026 AFS.

Margins and growth (analyst-derived)

Gross margin is not applicable to an investment entity. FY2023 margins are not meaningful because total income was negative.

Revenue CAGR. On the total-income basis no meaningful CAGR exists: income swung from negative in FY2023 to a peak in FY2024 and then fell. NAV CAGR FY2022–FY2026 is 4.95% a year (R903.96m to R1,096.83m). NAV per share CAGR over the same period is 4.95% (1,397.3c to 1,695.5c), because the share count was unchanged. From FY2021 to FY2026 the NAV CAGR is 4.89% a year (R864.08m to R1,096.83m).

Supplementary pre-period history (FY2020–FY2021, abridged audited results):

Sources: FY2020 and FY2021 abridged results (SENS).

Balance sheet

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment and Segment Assets & Liabilities

SegmentFY2022FY2023FY2024FY2025FY2026

Healthcare (RHBO) fair value (ZAR Mn)

835.67821.161,086.041,182.701,149.96

Financial services (RHFS) fair value (ZAR Mn)

86.339.296.983.003.00

Total financial assets at FVTPL (ZAR Mn)

922.00830.441,093.021,185.701,152.96

Healthcare share of portfolio (%)

90.6498.8899.3699.7599.74

Healthcare fair value change (ZAR Mn)

—-27.70252.9566.68-32.73

Financial services fair value change (ZAR Mn)

—-17.21-3.38-4.43-0.37

Healthcare YoY growth in fair value (%)

—-1.7432.268.90-2.77

Segment Assets & Liabilities and Segment Assets & Liabilities (%)

SegmentFY2023FY2024FY2025FY2026

Asset-heavy fair value (ZAR Mn)

804.67881.38912.10901.72

Asset-light fair value (ZAR Mn)

24.05200.16258.80239.11

Unallocated RHBO net assets (ZAR Mn)

1.7311.4914.8012.13

Asset-light share of portfolio (%)

2.9018.3121.8320.74

Asset-heavy fair value change (ZAR Mn)

—66.5929.94-5.50

Asset-light fair value change (ZAR Mn)

—183.0734.80-27.60

Asset-heavy YoY growth (%)

—9.533.49-1.14

Asset-light YoY growth (%)

—732.2729.30-7.61

Revenue by Segment

InvesteeFY2024FY2025FY2026

Africa Healthcare (ZAR Mn)

8.0815.1915.68

Rondebosch Medical Centre (ZAR Mn)

1.150.830.92

Medicare Private Hospital (ZAR Mn)

12.920.000.00

MMed Distribution Services (ZAR Mn)

4.001.411.47

Vryburg Private Hospital (ZAR Mn)

—2.172.46

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Per-Share Data

MetricFY2023FY2024FY2025FY2026

Interest income (ZAR Mn)

7.4314.688.045.71

Dividend income (ZAR Mn)

28.1322.1426.1483.69

Fair value gains/(losses) (ZAR Mn)

-55.62243.5972.05-36.16

Total investment income (ZAR Mn)

-20.07280.42106.2353.24

Other income (ZAR Mn)

4.244.445.650.18

Total income – revenue proxy (ZAR Mn)

-15.83284.86111.8953.42

Finance costs (ZAR Mn)

7.0319.9811.4711.05

Employee costs (ZAR Mn)

4.7911.6510.969.31

Management fees to RHBM (ZAR Mn)

4.077.426.794.51

Depreciation (ZAR Mn)

0.890.910.941.01

Expected credit loss charge/(release) (ZAR Mn)

0.000.001.17-1.17

Other operating expenses (ZAR Mn)

12.0012.6820.8513.51

Total expenses incl. finance costs (ZAR Mn)

28.7852.6452.1738.22

Operating income – EBIT, analyst-derived (ZAR Mn)

-37.58252.1971.1826.24

EBITDA, analyst-derived (ZAR Mn)

-36.69253.1072.1227.25

Profit/(loss) before tax (ZAR Mn)

-44.61232.2159.7115.20

Income tax (charge)/credit (ZAR Mn)

12.40-49.57-15.793.37

Net income / total comprehensive income (ZAR Mn)

-32.21182.6443.9318.57

Basic & diluted EPS (ZAR cents)

-49.8282.367.928.7

Headline EPS (ZAR cents)

-49.8282.367.928.7

Dividend per "A" share declared (ZAR cents)

03100

Margin Analysis (%) and Dividends & Capital Returns

MetricFY2022FY2023FY2024FY2025FY2026

Operating (EBIT) margin on total income (%)

——88.5363.6249.12

EBITDA margin on total income (%)

——88.8564.4651.01

Net margin on total income (%)

——64.1239.2634.76

Cash investment income – interest plus dividends (ZAR Mn)

—35.5536.8234.1889.40

Total expenses / average NAV (%)

—3.245.524.943.51

NAV growth (%)

4.62-3.5618.654.251.72

Income Statement and Per-Share Data (FY2020–FY2021)

MetricFY2020FY2021

Total investment income (ZAR Mn)

105.39188.83

Fair value gains (ZAR Mn)

84.06174.48

Total expenses (ZAR Mn)

16.9122.75

Profit before tax (ZAR Mn)

90.46166.52

Net income (ZAR Mn)

69.99131.22

Basic EPS (ZAR cents)

131218

NAV (ZAR Mn)

646.61864.08

NAV per share (ZAR cents)

1,1561,336

Total assets (ZAR Mn)

671.18925.68

Cash and equivalents (ZAR Mn)

120.0734.70

Dividend per "A" share declared (ZAR cents)

015

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Financial assets at FVTPL (ZAR Mn)

922.00830.441,093.021,185.701,152.96

Loans to related parties at FVTPL (ZAR Mn)

42.9848.2244.8355.6155.33

Cash and cash equivalents, gross (ZAR Mn)

7.76151.9354.7330.0227.24

Total assets (ZAR Mn)

—1,033.481,216.361,283.181,258.64

Short-term borrowings incl. overdraft (ZAR Mn)

0.00102.5121.6421.5524.96

Long-term borrowings (ZAR Mn)

0.000.0050.3549.570.00

Total debt excl. leases (ZAR Mn)

0.00102.5171.9971.1224.96

Lease liabilities (ZAR Mn)

2.982.271.450.482.79

Net debt excl. leases (ZAR Mn)

-7.76-49.4217.2641.10-2.28

Deferred tax liability (ZAR Mn)

68.8056.40105.97121.75118.38

Total liabilities (ZAR Mn)

—161.74182.03204.92161.81

Total equity / NAV (ZAR Mn)

903.96871.741,034.331,078.261,096.83

NAV per share (ZAR cents)

1,397.31,347.51,598.91,666.81,695.5

Goodwill & intangibles (ZAR Mn)

0.000.000.000.000.00

Net working capital – net current assets (ZAR Mn)

—63.5459.8512.2310.20

Shares in issue (millions)

64.6964.6964.6964.6964.69

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Cash used in operations (ZAR Mn)

—-16.85-33.24-22.96-22.06

Dividends received in cash (ZAR Mn)

—28.138.1435.3515.84

Interest received in cash (ZAR Mn)

—3.5311.772.601.38

Finance costs paid (ZAR Mn)

—-4.52-20.50-12.64-11.66

Net operating cash flow (ZAR Mn)

—10.28-33.832.34-16.50

Capex – PPE (ZAR Mn)

—0.050.080.050.00

Free cash flow – OCF less capex (ZAR Mn)

—10.24-33.912.29-16.50

Net cash invested in/(realised from) portfolio (ZAR Mn)

—-34.8312.2825.96-4.93

Net investing cash flow (ZAR Mn)

—34.78-12.36-26.014.93

Borrowings raised (ZAR Mn)

—100.000.000.0024.96

Borrowings repaid in cash (ZAR Mn)

—0.0030.0010.005.00

"A" share dividends paid (ZAR Mn)

9.700.0020.050.000.00

Share buybacks (ZAR Mn)

0.000.000.000.000.00

Net financing cash flow (ZAR Mn)

—99.10-51.01-11.0418.78

Net change in cash (ZAR Mn)

—144.17-97.20-34.707.21

Margin Analysis (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

ROE on average equity (%)

—-3.6319.164.161.71

ROA on closing total assets (%)

—-3.1215.023.421.48

ROIC – EBIT×(1-27%)/(equity+debt) (%)

—-2.8216.644.521.71

Current ratio (x)

—1.613.381.361.24

Debt/equity, interest-bearing (%)

0.0011.766.966.602.28

Total liabilities/equity (%)

—18.5517.6019.0014.75

Net debt/EBITDA (x)

——0.070.57-0.08

Interest coverage – EBIT/finance costs (x)

—-5.3512.626.212.38

Asset turnover – total income/total assets (%)

—-1.5323.428.724.24

Results by Region and Revenue by Region (%)

RegionFY2022FY2023FY2024FY2025FY2026

South Africa – total investment income (ZAR Mn)

—-20.07280.42106.2353.24

Rest of Africa incl. Rwanda – total investment income (ZAR Mn)

—0.000.000.000.00

South Africa – share of portfolio fair value (%)

100100100100100

Province Details

ProvinceFacilities

Free State

St Helena Hospital (Welkom)

Gauteng

Fochville Hospital; RH Pelo Carletonville Hospital; Fauchard Clinic (Florida, Roodepoort)

North West

Vryburg Private Hospital

Western Cape

Rondebosch Medical Centre (Cape Town)

—

Medicare, RH Bell, Platinum, The Fountain

“—” = not publicly disclosed.

Valuation Snapshot

MetricValueSource

Share price (latest observed, Oct 2026)

165c

TradingView

1-year performance

-17.09%

TradingView

Year-to-date

-17.50%

TradingView

3-year performance

Not available in the sources retrieved

—

5-year performance

-67.20%

TradingView

All-time performance

-83.82%; IPO price R10 (1,000c)

TradingView; SENS

All-time high / low

1,160c (28 Sep 2017) / 100c (20 Jul 2023)

TradingView

Beta (1Y)

0.60

TradingView (an earlier snapshot showed -0.55; unreliable given thin trading)

Liquidity

Very low; frequent "no trades" days. A 2024 independent commentary described the shares as almost untraded.

TradingView

Capital Markets

MetricRH Bophelo

Market capitalisation

R106.7m (TradingView: R112.56m)

Enterprise value (market cap + debt R24.96m + leases R2.79m − cash R27.24m)

about R107.2m

P/E (FY2026 EPS 28.7c)

5.7x (TradingView: about 6x)

P/NAV (P/B)

0.097x

EV/EBITDA (FY2026 EBITDA R27.25m)

3.9x

EV/Sales (total income R53.4m)

2.0x; on TradingView's R89.6m revenue definition (interest + dividends + other income), 1.2x

Dividend yield

0% (no FY2025 or FY2026 dividend)

Per-Share Data and Dividends & Capital Returns

MetricFY2021FY2022FY2023FY2024FY2025FY2026

"A" dividend per share declared (ZAR cents)

15—03100

"A" dividends paid in year (ZAR Mn)

0.009.700.0020.050.000.00

"B" share dividend declared (ZAR Mn)

0.003.900.000.000.000.00

Capital Instruments

InstrumentAmountTerms

Capitec short-term working-capital facility

R24.96m

Current; prime-linked; repayable monthly; reviewed annually

Office lease

R2.79m

R1.18m current, R1.62m non-current; runs to about Sep 2028

Analyst Conclusions

Management guidance

No quantitative guidance is provided. Qualitatively, management:

  • expects the asset-light strategy to keep supporting value through lower input costs and better margins;

  • regards the diversified, essential nature of its services as supporting resilience in earnings and cash flows;

  • notes continued macro headwinds and NHI uncertainty (FY2026 AFS, Directors' Report).

The going-concern statement covers the 12 months to 28 February 2027.

Consensus expectations

No sell-side coverage or consensus estimates were identified.

Bull case

  1. Discount is extreme relative to audited NAV. At about 0.10x NAV, the market implies roughly a 90% haircut to auditor-reviewed carrying values. Africa Healthcare alone is carried at R383.6m, about 3.6x the entire market capitalisation, and paid R15.7m of income in FY2026. Even severe haircuts to carrying values leave large implied upside per share.

  2. Holding-company balance sheet de-risked. Norsad has been repaid, holdco net debt is about nil, and the interest-bearing debt/equity ratio is 2.3%. Without the R4.48m early settlement fee, FY2027 finance costs should fall well below FY2026's R11.0m. Combined with lower fees (management fee down 34% to R4.5m), holdco costs could fall below R35m.

  3. Optionality in diagnostics and dialysis. RazoHealth (R40.8m) and Renal Healthcare Africa (R21.9m) are both still being revalued upward. A disclosed 15-centre radiology rollout and a dialysis JV with a specialist partner give organic growth that does not require large hospital capex.

Bear case

  1. NAV is model-driven and has been revised down. All investments are Level-3 DCF valuations at WACCs of 19–21%. The FY2024 NAV jump rested largely on revaluing MMed from R1 to R158m within ten months. MMed, Ambit, Medicare and Fauchard were all written down in FY2026. Without third-party transactions, NAV credibility is low and the discount may be rational.

  2. Minority shareholders have little leverage. The PIC owns 67%, the next holder 12%, and free float and liquidity are minimal. Costs (fees plus salaries via RHBM plus listing costs) absorb most cash income. "A" dividends have been paid in only two of nine years and none since December 2023.

  3. Cash generation is weak and leverage has moved down into the portfolio. Holdco operating cash flow was negative in two of the last three years. The FY2026 dividend was largely non-cash: Norsad was "refinanced at asset level", so debt moved into Africa Healthcare rather than being extinguished. Net current assets have fallen to R10m.

Key catalysts and monitorables (next 12 months)

Timing (expected)Catalyst / monitorable
Late Nov 2026 (based on prior pattern)H1 FY2027 interim results: NAV trend, cash dividends from RHBO, any further write-downs at MMed or Ambit, Capitec facility status
UnscheduledConstitutional Court NHI judgment (reserved since 7 May 2026) and any subsequent promulgation timetable
OngoingRazoHealth practice count against the referenced 15-centre plan; Renal Healthcare Africa performance
OngoingAny asset realisation at or near NAV (e.g. property sale, partial disposal) — the strongest test of carrying values
OngoingAfrica Healthcare's new asset-level debt: terms, covenants and impact on its valuation and dividend capacity (not disclosed in the retrieved sections)
OngoingPossible capital-allocation action to address the discount: dividend resumption, buyback, or a strategic transaction led by the PIC. None has been announced; this is analyst speculation, not a rumour.
May 2027FY2027 results and whether NAV growth clears the 10% "B" share hurdle

Concluding analyst verdict

RH Bophelo is best understood as a sub-scale, externally managed South African healthcare private-equity portfolio wrapped in a listed shell. On paper it is solid: R1.10bn of NAV, a holding company that is now effectively debt-free, clean audit opinions, Level-1 B-BBEE status, and a portfolio that spans hospitals, pharmaceutical distribution, radiology, dialysis and pathology. The anchor asset, Africa Healthcare, produces real cash income.

The market price tells a different story. At about R1.65 against reported NAV of R16.96, investors are valuing the company at roughly a tenth of its stated worth. The evidence in the filings explains much of that scepticism:

  • Reported earnings depend on unrealised Level-3 revaluations made at 19–21% discount rates.

  • The FY2024 NAV surge rested heavily on revaluing a business bought for R1, and that value was partly reversed two years later.

  • FY2026's apparent tripling of dividend income was mostly a non-cash transfer that moved holding-company debt down into the hospital portfolio.

  • Per-share NAV has compounded at under 5% a year since FY2021.

  • The holding company's running costs consume most of its cash income.

  • Two-thirds of the shares sit with the PIC, so minorities depend on a single state-owned shareholder for any catalyst.

The risk/reward is therefore binary rather than incremental. If a credible third-party transaction, partial realisation, or PIC-led corporate action validated even half of reported NAV, the upside per share would be several-fold. Without such an event, the discount can persist indefinitely. Meanwhile the NHI judgment, elective-procedure weakness and continued write-downs in the asset-light ventures could erode NAV further.

For institutional readers the stock is not investable on liquidity grounds alone. For special-situations or strategic investors, the key diligence questions are:

  1. the terms of the new Africa Healthcare debt;

  2. look-through EBITDA and cash conversion of the top five assets;

  3. the PIC's long-term intentions.

Our overall assessment is "deep value, low conviction". Fundamental asset backing appears real but unproven, and governance and structure, not operations, are the binding constraints on value realisation.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackground (as disclosed)FY2026 total remuneration (ZAR)

Quinton Zunga

Founder, CEO and executive director

Since incorporation (Dec 2016)

Born in Zimbabwe's Eastern Highlands. About 16 years in investment banking (including Barclays) and about 4 years in private equity at listing. Earlier advisory work for Busamed. Majority shareholder of RQ Capital Partners. Director of RHBM and RH Managers. Education and age not publicly disclosed.

3,048,979 (salary 2,725,401; bonus 323,578)

Yondie Metu ("AY Metu")

CFO and executive director

Since 1 Dec 2023

CA(SA). Prior roles, age and education beyond CA(SA) not publicly disclosed.

3,048,979 (salary 2,725,401; bonus 323,578)

Colin W. Clarke

Chief Investment Officer and executive director

Executive since at least FY2021 (earlier as non-executive per 2018 SENS)

Director of RHBM. Cross-directorships across most investees. Education and age not publicly disclosed.

2,849,280 (salary 2,544,000; bonus 305,280)

Directors' Remuneration

NameClassificationAppointed / tenureCommittees / notesFY2026 fees (ZAR)

Samson Moraba

Independent non-executive Chairman

Chairman since 11 Aug 2023; director before that

BCom, PMD. Left the ARC on 22 Aug 2025.

729,000

Dr Phetole David Sekete

Non-executive (not independent)

Since at least 2018

Medical doctor. A secondary source reports 33 years of medical experience. Cross-director of RHBO, Africa Healthcare and RH Managers.

453,000

Fulufhelo Makwetla

Non-executive (not independent)

Since at least 2018

Investment Committee member; director of RHBM

496,000

Romeo Makhubela

Independent non-executive

11 Aug 2023

ARC member. BCom, MFin, MPhil.

728,250

Carmen Mpelwane

Independent non-executive

17 Jan 2025

ARC chair from 15 Oct 2025. CA(SA), CFA. A secondary source describes her as a listed-equity portfolio manager with healthcare coverage.

494,750

Thanyani Mashau

Independent non-executive

17 Jan 2025

Committees not disclosed in the sources retrieved

406,500

Nontobeko S. Ndhlazi

Independent non-executive

15 Oct 2025

ARC member. BCom, PDip.

189,750

Quinton Zunga

Executive (CEO)

2016——

Yondie Metu

Executive (CFO)

2023——

Colin Clarke

Executive (CIO)

———

Bojane Segooa (former)

Independent non-executive; former ARC chair

Resigned 21 Aug 2025

CA(SA), MCom

175,000

Major Shareholders

ShareholderStakeAs atSource

Public Investment Corporation SOC Ltd

67.00%

28 Feb 2025

Profile's Stock Exchange Handbook 2025

Perthpark Properties

12.00%

28 Feb 2025

Profile's Handbook (PitchBook lists Perthpark as a former Rondebosch Medical Centre investor, consistent with shares issued for RMC in 2020)

"Dr Mandisa Joyce Gwendoline" (name as printed; possibly truncated)

3.00%

28 Feb 2025

Profile's Handbook

RQ Capital Partners (Pty) Ltd (CEO majority-owned)

about 3%

FY2025

FY2025 AFS, note 21

Other holders

about 15%

—

Residual (analyst-derived)

Competitive Landscape

Competitors by Segment

SegmentCompetitorOwnershipRelevance

Acute hospitals

Netcare Ltd

JSE-listed

Largest private hospital group; national footprint

Acute hospitals

Life Healthcare Group

JSE-listed

Second-largest listed hospital group; also in renal care

Acute hospitals

Mediclinic Southern Africa

Private (Mediclinic taken private in 2023 per general market knowledge; current financials not publicly comparable)

Major competitor, including Mediclinic Welkom near St Helena

Acute hospitals

Lenmed Health

Private

Independent hospital group targeting similar peri-urban markets

Acute hospitals

Clinix Health Group

Private

Township/peri-urban private hospitals; direct overlap with RH Bophelo's affordable-care thesis

Acute hospitals

Busamed

Private

Independent group; the CEO previously advised it

Acute hospitals (Western Cape)

Melomed Hospital Holdings

Private

Cape Town independent group; competes with Rondebosch Medical Centre

Pharmaceutical distribution

United Pharmaceutical Distributors (Clicks Group)

JSE-listed parent

Leading full-line pharma wholesaler; competes with MMed/1-Pharma

Pharmaceutical distribution

Dis-Chem (wholesale arm)

JSE-listed

Pharmacy retail and wholesale

Pathology

Lancet Laboratories, Ampath, PathCare

Private

The three dominant private pathology groups; compete with Ambit/Pelo

Dialysis

National Renal Care; Life Healthcare renal (incl. the former Fresenius SA assets referenced in Life's FY2025 interims)

Private / JSE-listed

Compete with Renal Healthcare Africa

Benefits administration

Discovery Health, Medscheme (AfroCentric)

Listed / private

Dominant administrators (HMI: 76% of administrator market by GCI); compete with Wesmart

Peer Comparison FY2026

MetricRH Bophelo (FY2026, y/e Feb 2026)Netcare (FY2025, y/e Sep 2025)Life Healthcare (FY2025, y/e Sep 2025)

Revenue / revenue proxy (ZAR Mn)

53.4 (total income, company-only)

26,344

25,100 (continuing operations)

Revenue growth (%)

-52.34.56.0

EBITDA (ZAR Mn)

27.3 (analyst-derived, company-only)

4,912 (normalised)

3,800 (normalised)

EBITDA margin (%)

51.0 (on investment income; not comparable)

18.6

about 15 (analyst-derived)

Net debt / EBITDA (x)

-0.08 (holdco)

1.1 (excluding IFRS 16)

—

Recent Developments

Not observed in the period: layoffs or hiring announcements, litigation, regulatory sanctions, guidance revisions or new acquisitions. H1 FY2027 interim results (to 31 August 2026) had not been published* as at 14 October 2026.

Company Snapshot

742

Employees

2016

Founded

SWOT Analysis

Strengths

  • NAV scale and stability. NAV of R1,096.8m at FY2026, above R1bn for three consecutive years (FY2024–FY2026 AFS).
  • Low holding-company leverage. Interest-bearing debt fell to R24.96m in FY2026 from R71.12m in FY2025 and R102.51m in FY2023. Holdco net debt excluding leases is -R2.3m (FY2026 AFS).
  • Anchor asset generating cash. Africa Healthcare (R383.6m, 33% of portfolio) paid R15.7m in income in FY2026 and R15.2m in FY2025 (note 6.2).
  • Diversification across the care chain: hospitals, pharmaceutical distribution, radiology, dialysis, pathology and administration (FY2026 related-party list).
  • Transformation credentials: B-BBEE Level 1 (SENS, 27 Jul 2026), with a founding identity as the first black-owned and black-managed listed healthcare company (Fin24, 2017).
  • Clean audits and strengthened audit oversight: unmodified opinions, no reportable irregularities, no non-audit services (FY2024–FY2026 ARC reports). The new ARC chair is a CA(SA) and CFA (Oct 2025).

Weaknesses

  • Earnings quality. FY2024 profit of R182.6m was 133% explained by fair-value gains of R243.6m. The FY2026 dividend of R83.7m was about 81% non-cash, with R15.8m received in cash.
  • Slow per-share compounding. NAV per share CAGR of about 4.9% over FY2021–FY2026, below the 10% "B" share hurdle and below the 19–21% WACCs used in valuations.
  • Cost burden. Total expenses of R38–53m a year against a market capitalisation of about R107m. Management fees of R4.5–7.4m sit on top of salaries paid via RHBM.
  • Thin holdco liquidity. Net current assets fell from R59.8m (FY2024) to R10.2m (FY2026). Operating cash flow was negative in FY2024 (-R33.8m) and FY2026 (-R16.5m).
  • Low transparency. No consolidated or look-through revenue, EBITDA, bed or occupancy data. Investee net assets are unaudited. Rondebosch shows negative attributable net assets of -R386m.
  • Weak write-down record in asset-light bets. Locumbase went to nil, Wesmart fell from R9.3m to R3.0m, Ambit fell from R13.9m to R5.9m, and MMed lost R23.1m in FY2026 (note 6.6).

Opportunities

  • Market re-rating. The share trades at about 0.10x NAV. Any credible realisation of assets near carrying value would crystallise large per-share value (analyst-derived from 165c vs 1,695.5c).
  • Diagnostics scale-up. RazoHealth went from 3 to 4 practices and the FY2025 IAR summary references a 15-centre rollout.
  • Dialysis demand. Renal Healthcare Africa was revalued up by R11.5m in FY2025 and R2.1m in FY2026.
  • NHI contracting. Management explicitly sees potential participation in future state-led contracting frameworks (FY2026 AFS).
  • Debt capacity. The stated 30% gearing ceiling against 14.8% current gearing leaves room for growth financing.
  • Regional expansion. The RSE listing and the IFC partnership (2020–2021) provide a platform for East African or sub-Saharan expansion that has not yet been used.

Threats

  • NHI uncertainty. Funding-flow and pricing risks are acknowledged by the company. Constitutional Court judgment remains reserved (May 2026).
  • Macro pressure on elective procedures. Cited in each Directors' Report from FY2024 to FY2026.
  • Concentration of competitors. The big three hold about 83% of beds (HMI), which limits funder negotiating leverage for small independents.
  • Valuation-input risk. Combined unfavourable sensitivity of -R79.6m (about 7% of the portfolio) from 50bp/250bp shocks (FY2026 note 6.3). Property cap rates are being raised, for example St Helena to 14%.
  • Currency and trade risk. The FY2025 Directors' Report specifically identifies rand weakness and US–SA tensions as risks to equipment and pharmaceutical costs.
  • Shareholder concentration. The PIC's 67% stake makes the minority's outcomes dependent on one state-owned asset manager's decisions (Profile's 2025).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Mar 2025R5.5m working-capital loan to MMed (1-Pharma)Continued funding need in the asset-light flagship
30 May 2025FY2025 audited results: NAV R1,078m (+4%), profit R43.9m, EPS 67.9c, no dividendGrowth slowed sharply after FY2024
30 May 2025FY2025 AFS flagged US–SA trade-relations risk to procurement costs, capital access and expansionNew macro risk disclosure
30 May 2025FY2025 AFS disclosed a one-off R10.98m VAT apportionment adjustmentExplains the jump in expenses
30 Jun 2025FY2025 Integrated Annual Report and AGM notice distributedGovernance calendar
3 Jul 2025FY2025 IAR posted on the RSE information platform (AfricanFinancials)RSE disclosure
21 Aug 2025ARC chair Bojane Segooa resigned with immediate effectAudit-committee leadership change on the eve of the AGM
22 Aug 2025AGM: resolutions on Segooa's re-election withdrawn; remaining resolutions passed, with 88.84% of shares representedGovernance continuity
22 Aug 2025Chairman Moraba stepped off the ARCARC composition change
Sep 2025Original five-year office lease expired; R0.11m advance to FauchardMinor
Oct 2025Three-year office lease extension with the related-party landlordOngoing related-party arrangement
15–16 Oct 2025Nontobeko Ndhlazi appointed INED and ARC member; Carmen Mpelwane named ARC chairStrengthened audit oversight (CA(SA), CFA chair)
25 Nov 2025H1 FY2026 interim results: NAV R1,097m (+4% YoY), EPS 29.44c, investment income -18% to R44m (dividend timing), lower expensesInterim stability
FY2026 (date not specified)Norsad facility discharged and refinanced at asset level (Africa Healthcare); R4.48m early settlement feeDebt moved off the holding-company balance sheet
FY2026 (date not specified)Capitec short-term facility drawn (R24.96m); FNB overdraft closedLiquidity restructuring
FY2026R2.0m into RazoHealth; 4 radiology practices operationalAsset-light expansion
24 Feb 2026Presidency undertakes not to promulgate the NHI Act pending Constitutional Court judgment on public-participation challenges; High Court cases stayedDefers NHI-related uncertainty
28 Feb 2026 (valuation date)Year-end write-downs: MMed -R23.1m, Medicare -R14.3m, Ambit -R8.0m, Fauchard -R5.1mReversal of part of the FY2024–FY2025 asset-light gains
28 Feb 2026 (valuation date)Africa Healthcare property list reduced to St Helena only (R46m, cap rate raised to 14% from 11%)Property derating; Fochville property no longer included
Before 29 May 2026JSE sponsor changed from Deloitte & Touche Sponsor Services to BSM SponsorsAdviser change
5–7 May 2026Constitutional Court heard the NHI public-participation challenges (BHF and Western Cape Government) and reserved judgmentKey sector catalyst outstanding
29 May 2026FY2026 audited results: NAV R1,096.8m (+2%), profit R18.6m, EPS 28.7c, dividend income R83.7m, fair-value loss R36.2m, no dividend; segments redefinedLowest NAV growth since FY2023
15 Jun 2026FY2026 annual report posted for RSE investorsRSE disclosure
30 Jun 2026FY2026 IAR and AGM notice distributedGovernance calendar
27 Jul 2026B-BBEE annual compliance report: Level 1Transformation credentials maintained
20 Aug 2026AGM: all ordinary and special resolutions passed; 87.23% of shares representedShareholder support
Oct 2026Share price about 165c; -17% over 1 year and YTD; -67% over 5 years (TradingView)Discount to NAV about 90%

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Income Statement: Revenue & Gross Profit: Total income – revenue proxy rose from ZAR -15.8 Mn in FY2023 to ZAR 53.4 Mn in FY2026.
RH Bophelo Limited — Income Statement: Revenue & Gross Profit
Series (ZAR Mn)FY2023FY2024FY2025FY2026
Total income – revenue proxy-15.8284.9111.953.4

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. FY2026 Annual Financial Statements (year ended 28 Feb 2026), signed 29 May 2026 (rhbophelo.co.za)
  2. FY2025 Annual Financial Statements (senspdf.jse.co.za)
  3. FY2024 Annual Financial Statements (senspdf.jse.co.za)
  4. FY2024 short-form results (27 May 2024) (senspdf.jse.co.za)
  5. FY2025 short-form results (30 May 2025) (sharedata.co.za)
  6. H1 FY2026 short-form interim results (25 Nov 2025) (sharedata.co.za)
  7. H1 FY2025 interim results (senspdf.jse.co.za)
  8. H1 FY2024 interim results (senspdf.jse.co.za)
  9. H1 FY2022 interim results (senspdf.jse.co.za)
  10. FY2021 abridged results (senspdf.jse.co.za)
  11. H1 FY2021 reviewed interim results (senspdf.jse.co.za)
  12. FY2020 reviewed provisional results (senspdf.jse.co.za)
  13. SENS 5 Jul 2017 (pre-listing statement) (sharedata.co.za)
  14. SENS 22 Nov 2017 (acquisition of assets) (sharedata.co.za)
  15. SENS 8 Feb 2018 (board committees) (sharedata.co.za)
  16. SENS 23 Feb 2018 (circular) (sharedata.co.za)
  17. SENS 22 Aug 2025 (withdrawal of resolutions) (sharedata.co.za)
  18. SENS 22 Aug 2025 (AGM results) (sharedata.co.za)
  19. SENS 30 Jun 2026 (IAR and AGM notice) (sharedata.co.za)
  20. SENS 27 Jul 2026 (B-BBEE) (sharedata.co.za)
  21. SENS 20 Aug 2026 (AGM results) (sharedata.co.za)
  22. SENS 22 Aug 2024 (AGM results) (senspdf.jse.co.za)
  23. Profile's Stock Exchange Handbook 2025 Issue 4, p.183 (sharedata.co.za)
  24. TradingView JSE:RHB (in.tradingview.com)
  25. AfricanFinancials — FY2026 annual report summary (africanfinancials.com)
  26. AfricanFinancials — FY2025 IAR summary (africanfinancials.com)
  27. AfricanFinancials — H1 FY2026 summary (africanfinancials.com)
  28. AfricanFinancials — company page (africanfinancials.com)
  29. FilingReader (FY2026 results) (filingreader.com)
  30. IFC press release, 9 Dec 2021 (ifc.org)
  31. Fin24, JSE listing (Jul 2017) (fin24.com)
  32. Business Day (Jul 2017) (businesslive.co.za)
  33. Business Day (Jul 2017) (businesslive.co.za)
  34. Fin24, "The deliberate disruptor" (Jun 2018) (fin24.com)
  35. The EastAfrican (RSE listing) (theeastafrican.co.ke)
  36. African Markets (RSE listing) (african-markets.com)
  37. PitchBook, Rondebosch Medical Centre (pitchbook.com)
  38. TradingView investor commentary (tradingview.com)
  39. Netcare FY2025 results (netcare.co.za)
  40. Life Healthcare FY2025 results (lifehealthcare.co.za)
  41. BizNews, Life Healthcare FY2025 (biznews.com)
  42. Health Market Inquiry coverage (BusinessTech) (businesstech.co.za)
  43. Health Market Inquiry coverage (BusinessTech) (businesstech.co.za)
  44. NHI litigation (TimesLive) (timeslive.co.za)
  45. NHI litigation (EWN) (ewn.co.za)
  46. NHI litigation (Moonstone) (moonstone.co.za)
  47. Medical-scheme network lists (lahealth.co.za)
  48. Bankmed DSP list (bankmed.co.za)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.